| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/02/2000 | US6057338 Useful in the treatment of diabetes, cancer, acromegaly, restenosis, depression, irritable bowel syndrome, pain and diabetic retinopathy |
| 05/02/2000 | US6057336 Lactam metalloprotease inhibitors |
| 05/02/2000 | US6057334 Benzo[g]quinoline derivatives |
| 05/02/2000 | US6057332 Substituted 1,4-dihydropyrimidine-5-carboxylate compounds, their preparation and uses |
| 05/02/2000 | US6057330 Pyrrolopyrazolopyrimidine compound and medicine comprising the same as active ingredient |
| 05/02/2000 | US6057329 Inhibitors of the protein tyrosine kinases and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases |
| 05/02/2000 | US6057328 Treating conditions resulting from hyperoxia, and in particular, conditions resulting from therapeutic administration of oxygen comprising administering xanthine compounds |
| 05/02/2000 | US6057327 Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections |
| 05/02/2000 | US6057326 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| 05/02/2000 | US6057325 Have central dopamine and serotonin antogonistic activity |
| 05/02/2000 | US6057324 Substituted amidinobenzene derivatives and medicinal compositions thereof |
| 05/02/2000 | US6057323 Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
| 05/02/2000 | US6057321 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application |
| 05/02/2000 | US6057320 Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| 05/02/2000 | US6057318 Heterocyclic derivatives, process for their preparation and their therapeutic use |
| 05/02/2000 | US6057317 Heterocyclic compounds |
| 05/02/2000 | US6057312 Cephalosporin antibiotics |
| 05/02/2000 | US6057309 Treating osteoporosis |
| 05/02/2000 | US6057308 Preparation comprising taurine and gamma-oryzanol |
| 05/02/2000 | US6057307 Use of mometasone furoate for treating airway passage and lung diseases |
| 05/02/2000 | US6057306 Method of treating the navicular disease in horses |
| 05/02/2000 | US6057305 Antiretroviral enantiomeric nucleotide analogs |
| 05/02/2000 | US6057302 Administering sophorolipids to stimulate synthesis of collagen; preventing skin aging |
| 05/02/2000 | US6057301 Moisture resistant, improved storage stability |
| 05/02/2000 | US6057300 Introducing expression vector comprising gene encoding p21 and expression vector comprising second gene encoding immunotherapeutic agent, genetic therapeutic, cytokine or prodrug converting enzyme to treat restenosis |
| 05/02/2000 | US6057292 Method for inhibiting growth hormone action |
| 05/02/2000 | US6057156 Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
| 05/02/2000 | US6057132 Nucleotide sequences encoding apoptosis associated Bbk protein |
| 05/02/2000 | US6056977 Once-a-day controlled release sulfonylurea formulation |
| 05/02/2000 | US6056975 Levothyroxine sodium, polysaccharide |
| 05/02/2000 | US6056974 Rapid-release S1452 tablets |
| 05/02/2000 | US6056972 Method for reducing coronary artery reactivity |
| 05/02/2000 | US6056971 Coenzyme q(ubiquinone), orally delivered soft gelatin capsule, nonionic surfactant solubilizer with a polyhydric alcohol |
| 05/02/2000 | US6056968 Pharmaceutical drug dosage forms providing different release rates |
| 05/02/2000 | US6056966 Organic mono- or dinitrate in a pharmaceutically acceptable topical or parenteral carrier |
| 05/02/2000 | US6056961 Plant extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
| 05/02/2000 | US6056960 Pertussis toxin and its analogs exhibiting adp-ribosyltransferase activity; tumor-related antigen comprising tumor cells, irradiated tumor cells, or tumor-associated antigens |
| 05/02/2000 | US6056959 CD40 antigen antibody complex |
| 05/02/2000 | US6056944 Pharmaceutical compositions for oral use including an NSAID and ceramides |
| 05/02/2000 | US6056715 Surgical irrigation solution and method for inhibition of pain and inflammation |
| 05/02/2000 | CA2224616C Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide |
| 05/02/2000 | CA2137176C Liponucleotide compounds |
| 05/02/2000 | CA2136411C Immediate release tablet cores of insoluble drugs having sustained release coating |
| 05/02/2000 | CA2115427C Novel 4-oxocyclic ureas useful as antiarrhythmic and antifibrillatory agents |
| 05/02/2000 | CA2105057C Dna sequences which code for virulence characteristics of streptococcus suis and part thereof polypeptides and antibodies derived therefrom and the use thereof for the diagnosis of and protection against infection by s. suis in mammals, including man |
| 05/02/2000 | CA2104686C Delayed release oral dosage forms for treatment of intestinal disorders |
| 05/02/2000 | CA2090024C Phospholipid derivatives of nucleosides, their preparation, as well as their use as anti-viral medicaments |
| 05/02/2000 | CA2076018C Docosahexaenoic acid, methods for its production and compounds containing the same |
| 05/02/2000 | CA2069961C Method and compositions for inhibition of disorders associated with oxidative damage |
| 05/02/2000 | CA2022372C Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives |
| 05/02/2000 | CA2020838C Hemoregulatory peptides |
| 05/02/2000 | CA2012480C Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| 05/02/2000 | CA2006267C Method of treating herpesviruses |
| 05/02/2000 | CA2004784C Anti-aids virus agent 2-amino-6-chlorpurine-9-.beta.-2,'3'-dideoxyribofuranoside |
| 05/02/2000 | CA2003009C Method and composition for reducing postsurgical adhesions |
| 04/30/2000 | CA2288386A1 Antithrombotic agents |
| 04/28/2000 | CA2287549A1 Antithrombotic agents |
| 04/27/2000 | WO2000023618A1 Polymorphism in a tgf-beta gene correlated to osteoporosis |
| 04/27/2000 | WO2000023599A2 Human proteins involved in endoplasmic reticulum protein degradation |
| 04/27/2000 | WO2000023588A2 G-protein coupled receptors |
| 04/27/2000 | WO2000023572A1 Tnfr related gene 12 |
| 04/27/2000 | WO2000023568A2 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
| 04/27/2000 | WO2000023468A1 HUMAN PROTEINS STAM2a AND STAM2b AND cDNAS ENCODING THESE MOLECULES |
| 04/27/2000 | WO2000023460A1 HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE |
| 04/27/2000 | WO2000023457A1 Adenine derivatives |
| 04/27/2000 | WO2000023454A1 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 04/27/2000 | WO2000023451A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023449A1 Pyrazolo-triazine derivatives as ligands for gaba receptors |
| 04/27/2000 | WO2000023448A1 Novel pterin antineoplastic agents |
| 04/27/2000 | WO2000023447A1 Adenosine analogues having antihypertensive, cardioprotective, anti-ischemic antilipolytic properties |
| 04/27/2000 | WO2000023445A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023441A1 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 04/27/2000 | WO2000023439A1 Vitreous form of known bradykinin antagonist |
| 04/27/2000 | WO2000023438A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h3 agonists or antagonists |
| 04/27/2000 | WO2000023433A1 Substituted benzopyran analogs for the treatment of inflammation |
| 04/27/2000 | WO2000023430A1 Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors |
| 04/27/2000 | WO2000023426A1 Novel imidazoles with anti-inflammatory activity |
| 04/27/2000 | WO2000023425A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023424A1 Epibatidine analogues as acetylcholine receptor antagonists |
| 04/27/2000 | WO2000023423A1 Method for producing (+)-exo-6-phenyl-3-azabicyclo-[3.2.0]heptanes |
| 04/27/2000 | WO2000023421A1 (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 04/27/2000 | WO2000023417A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023416A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023415A1 New compounds, their preparation and use |
| 04/27/2000 | WO2000023407A2 Ureido-thiobutyric acid derivatives as ppar-agonists |
| 04/27/2000 | WO2000023126A2 Methods for treating superficial bladder carcinoma |
| 04/27/2000 | WO2000023115A1 TREATMENT OF TRAUMA (I.E. GRAFT REJECTION) WITH LIPOSOMES CONTAINING DNA ENCODING FOR CTLA4Ig OR FOR ANTI-CD40L |
| 04/27/2000 | WO2000023112A1 Modulation of gene expression by combination therapy |
| 04/27/2000 | WO2000023102A1 Method for regulating the permeability of the blood brain barrier |
| 04/27/2000 | WO2000023100A2 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 04/27/2000 | WO2000023096A2 Combination therapy with vip antagonist |
| 04/27/2000 | WO2000023093A1 Compositions and methods for promoting tissue repair using heat shock proteins |
| 04/27/2000 | WO2000023089A1 Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid |
| 04/27/2000 | WO2000023087A1 Polyspecific binding molecules and uses thereof |
| 04/27/2000 | WO2000023086A2 Buffered compositions for dialysis |
| 04/27/2000 | WO2000023085A1 Mastitis treatment with particulate glucan |
| 04/27/2000 | WO2000023081A1 Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity |
| 04/27/2000 | WO2000023080A1 IMPROVING MEMORY BY THE ADMINISTRATION OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE AND 3β ESTERS THEREOF |
| 04/27/2000 | WO2000023079A1 Oral pharmaceutical compositions containing buprenorphin |
| 04/27/2000 | WO2000023078A1 Pharmaceutical compositions containing tetrahydroisoquinoline compounds |